comparemela.com

Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced today a new peer-reviewed study published using the Tapestri Platform's single-cell multi-omics solution to accurately distinguish leukemic cells from clonal hematopoiesis of indeterminate potential (CHIP) in relapsed AML patients. These findings highlight the potential of single-cell proteogenomics to vastly improve disease monitoring post-treatment, specifically for measurable residual disease (MRD) in hematological malignancies. The study was led by Christopher S. Hourigan, MD, DPhil, Chief of Myeloid Malignancies at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, and published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Related Keywords

Laura Dillon ,Yan Zhang ,Agilent Technologies ,Consort Partners For Mission Bio ,Mayfield Fund ,Mission Bio ,Tapestri Platform ,Novo Growth ,Cota Capital ,Na Sequencing ,Hematological Malignancies ,Christophers Hourigan ,லாரா டில்லன் ,யான் ஜாங் ,மனைவி கூட்டாளர்கள் க்கு பணி உயிர் ,மேஃபீல்ட் நிதி ,பணி உயிர் ,நோவோ வளர்ச்சி ,கோட்டா மூலதனம் ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.